A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Safety and Efficacy of Ad5FGF-4 in Patients With Refractory Angina Due to Myocardial Ischemia
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Jan 2018
At a glance
- Drugs Alferminogene-tadenovec (Primary)
- Indications Angina pectoris; Myocardial infarction
- Focus Therapeutic Use
- Acronyms AFFIRM
- Sponsors Angionetics
- 08 Jan 2018 Planned End Date changed from 1 Mar 2020 to 1 Jun 2021.
- 08 Jan 2018 Planned primary completion date changed from 1 Sep 2019 to 1 Jun 2020.
- 08 Jan 2018 Planned initiation date changed from 1 Sep 2017 to 1 Jun 2018.